Top 20 Pharma Report

July 16, 2013

Our annual look at the 20 biggest players in the Pharmaceutical marketplace

Patent expirations and currency swings were the big stories for Top Pharma revenues in 2012. Cumulatively, our Top 20 companies saw revenues fall 3% to $448 billion last year, although their net income for that span was virtually flat, at $93 billion. Our top six companies all saw revenues fall last year as they reload for the future. The only companies to show double-digit gains relied on generics (Mylan), an acquisition (Teva, getting a full year of Cephalon revenues) or out-and-out sales growth (Gilead).

Nonetheless, the ranking remained relatively stable (we included last year’s position in the chart on the right for reference). That likely won’t be the case next year, with shakeups due to further generic erosion and AbbVie’s shift over to the Top Biopharma ranks. In fact, as more Tops Pharmas derive greater shares of revenue from their biologics programs, we may have to rethink the whole Pharma/Biopharma split in a few years. . . 

—Gil Y. Roth

Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks
The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com)
Pipeline information compiled by Kristin Brooks
Revenue information compiled by Gil Roth

Photo courtesy of Eli Lilly & Co.

Top 20 Pharmaceutical Companies
based on 2012 pharma revenues

1 Pfizer $51,214 (prev.: 1)
2 Novartis $46,732 (prev.: 2)
3 Merck $40,601 (prev.: 4)
4 Sanofi $38,259 (prev.: 3)
5 GlaxoSmithKline $33,787 (prev.: 5)
6 AstraZeneca $27,973 (prev.: 6)
7 Johnson & Johnson $25,351 (prev.: 7)
8 Abbott Laboratories $23,133 (prev.: 9)
9 Eli Lilly & Co. $20,566 (prev.: 8)
10 Teva $18,535 (prev.: 12)
11 Bristol-Myers Squibb $17,621 (prev.: 10)
12 Takeda $16,961 (prev.: 11)
13 Boehringer-Ingelheim $14,665 (prev.: 13)
14 Bayer $13,890 (prev.: 14)
15 Astellas $12,168 (prev.: 15)
16 Daiichi-Sankyo $11,504 (prev.: 16)
17 Otsuka $10,295 (prev.: 17)
18 Gilead $9,398 (prev.: 18)
19 Mylan $6,750 (prev.: 20)
20 EISAI $6,647 (prev.: 19)

Note: In all Top Company profiles, dollar amounts are in millions.

Related Packaging:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks